南微医学
(688029)
| 流通市值：120.24亿 | | | 总市值：120.24亿 |
| 流通股本：1.88亿 | | | 总股本：1.88亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 699,156,940.3 | 2,755,434,907.16 | 2,012,446,160.41 | 1,333,844,008.46 |
| 营业收入 | 699,156,940.3 | 2,755,434,907.16 | 2,012,446,160.41 | 1,333,844,008.46 |
| 二、营业总成本 | 501,585,822.52 | 2,064,317,241.62 | 1,467,685,015.45 | 958,202,375.17 |
| 营业成本 | 239,887,378.33 | 891,287,564.51 | 651,175,548.98 | 427,674,897.51 |
| 税金及附加 | 8,649,611.75 | 33,256,403.48 | 23,328,191.94 | 15,513,738.19 |
| 销售费用 | 149,159,764.01 | 646,301,355.07 | 465,159,798.73 | 303,232,123.84 |
| 管理费用 | 97,383,711.02 | 368,831,423.56 | 249,161,760.14 | 165,850,464.83 |
| 研发费用 | 38,058,328.95 | 174,369,113.18 | 111,568,259.5 | 69,580,698.86 |
| 财务费用 | -31,552,971.54 | -49,728,618.18 | -32,708,543.84 | -23,649,548.06 |
| 其中:利息费用 | 819,271.92 | 3,314,203.53 | 2,016,604.94 | 1,704,427.12 |
| 其中:利息收入 | 14,228,994.46 | 72,032,930.77 | 52,756,958.52 | 36,200,403.22 |
| 加:公允价值变动收益 | -7,595.89 | -472,933.8 | -6,431.02 | -145,593.34 |
| 加:投资收益 | 3,567,616.18 | 20,504,100.32 | 15,371,554.09 | 10,997,694.12 |
| 资产处置收益 | 32,402.17 | 722,720.64 | 7,295.87 | 7,295.87 |
| 资产减值损失(新) | -4,077,077.94 | -56,873,239.97 | -18,458,996.41 | -12,511,305.14 |
| 信用减值损失(新) | -1,424,241.01 | -5,541,279.32 | -5,049,438.24 | -4,788,715.71 |
| 其他收益 | 2,276,694.32 | 9,954,779.68 | 3,456,377.66 | 2,477,697.95 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 197,938,915.61 | 659,411,813.09 | 540,081,506.91 | 371,678,707.04 |
| 加:营业外收入 | 125,262.08 | 1,063,989.52 | 2,402,579.67 | 1,506,204.42 |
| 减:营业外支出 | 274,671.75 | 702,448.35 | 237,479.97 | 89,819.83 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 197,789,505.94 | 659,773,354.26 | 542,246,606.61 | 373,095,091.63 |
| 减:所得税费用 | 30,627,234.93 | 91,696,122.23 | 78,213,733.65 | 53,096,345.54 |
| 六、净利润 | 167,162,271.01 | 568,077,232.03 | 464,032,872.96 | 319,998,746.09 |
| 持续经营净利润 | 167,162,271.01 | 568,077,232.03 | 464,032,872.96 | 319,998,746.09 |
| 归属于母公司股东的净利润 | 160,936,939.7 | 553,226,633.36 | 451,093,598.62 | 310,462,903.96 |
| 少数股东损益 | 6,225,331.31 | 14,850,598.67 | 12,939,274.34 | 9,535,842.13 |
| (一)基本每股收益 | 0.86 | 2.95 | 2.41 | 1.66 |
| (二)稀释每股收益 | 0.86 | 2.95 | 2.41 | 1.66 |
| 八、其他综合收益 | 9,159,697.47 | 1,494,630.66 | -1,088,120.39 | -2,329,147.63 |
| 归属于母公司股东的其他综合收益 | 6,603,994.48 | 1,497,191.74 | -1,089,950.81 | -2,328,097.77 |
| 九、综合收益总额 | 176,321,968.48 | 569,571,862.69 | 462,944,752.57 | 317,669,598.46 |
| 归属于母公司股东的综合收益总额 | 167,540,934.18 | 554,723,825.1 | 450,003,647.81 | 308,134,806.19 |
| 归属于少数股东的综合收益总额 | 8,781,034.3 | 14,848,037.59 | 12,941,104.76 | 9,534,792.27 |
| 公告日期 | 2025-04-29 | 2025-04-29 | 2024-10-30 | 2024-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |